210344-97-1
210344-97-1 结构式
基本信息
化合物Z-YVAD-FMK
L-Alaninamide, N-[(phenylmethoxy)carbonyl]-L-tyrosyl-L-valyl-N-[(1S)-3-fluoro-1-(2-methoxy-2-oxoethyl)-2-oxopropyl]- (9CI)
物理化学性质
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2025/05/22 | S8507 | MVPQJUFFTWWKBT-LBDWYMBGSA-N Z-YVAD-FMK | 210344-97-1 | 5mg | 4370元 |
| 2025/05/22 | S8507 | Z-YVAD-FMK | 210344-97-1 | 10mM (1mL in DMSO) | 5135.13元 |
| 2025/05/22 | S8507 | Z-YVAD-FMK | 210344-97-1 | 25mg | 13423.9元 |
常见问题列表
| Target | Value |
|
caspase-1
() |
Z-YVAD-FMK (100 μM; 24 hours) significantly downregulated the growth inhibition induced by butyrate in Caco-2 cells. Z-YVAD-FMK (20 μM; pre 1 hour; 24 hours) attenuates the apoptotic induction of III-10 on both HepG2 and BEL-7402 cells, the apoptotic rate of -10 on HepG2 cells is reduced by Z-VAD-FMK from 19.88% to 8.34%, while that on BEL-7402 cells is reduced from 17.56% to 11.98%. Z-YVAD-FMK (1-10 μM; 24 hours) shows inhibitory effect in various cells against TNFr- or anti-CD95-induced cell death, exhibits IC 50 values of 0.0015 μM (Murine hepatocytes), 0.027 μM (Murine hepatocytes), 4.8 μM (HepG2), 5.8 μM (HepG2), 1.6 μM (Hela) and 1.1 μM (Jurkat), respectively.
Cell Viability Assay
| Cell Line: | Caco-2 cells |
| Concentration: | 0-100 μM |
| Incubation Time: | 24 hours |
| Result: | Inhibited Caco-2 cells growth. |
Apoptosis Analysis
| Cell Line: | BEL-7402 and HepG2 cells |
| Concentration: | 20 μM |
| Incubation Time: | Pre 1 hour; 24 hours |
| Result: | Induced a caspase-dependent apoptosis in cells. |
Z-VAD-FMK (intraperitoneal injection; 10mg/kg; pre- 30 minutes) significantly delayed preterm delivery at 18 hours, but after 36 hours treatment, non different exists between Z-VAD-FMK-pretreated and control groups.
| Animal Model: | Day 14.5 pregnant CD1 mice |
| Dosage: | 10 mg/kg |
| Administration: | Intraperitoneal injection; 10mg/kg; pre-30 minutes |
| Result: | Prevented HK-GBS-induced preterm delivery. |